5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The market is segmented by Type(Statins, Non-statins) and Geography
Fastest Growing Market:
Lipids are important biomolecules, for example cholesterol acts as precursor for steroid hormones and bile acids. However, any kind of lipid in excess is not good for health. Lipid regulators, apart from cholesterol control, deal with fragile bones with high susceptibility to break which is termed as Osteoporosis and also they keep a check on myocardial infarctions which is commonly known as heart attack.
Recently due to increase in prevalence of diseases like Dyslipidemia, have increased the demand for lipid regulators. Dyslipidemia increases the chance of clogged arteries (atherosclerosis) and heart attacks, stroke or other circulatory concerns, especially in smokers. Moreover, geriatric population is more prone to cardiovascular diseases. In the elderly age group, lipid-altering medication has been proven to reduce cardiovascular risk.
Hence, these factors are helping the growth of the market. However, lack of awareness regarding the lipid regulators and presence of low-cost generics have been hindering the market growth.
Lipid regulators or lipid-regulating drugs are used to treat dyslipidemias, cardiovascular problems, osteoporosis and post-menopause complications. This is why these lipid regulators come under class of most prescribed medications.
In the report, a detailed analysis of the lipid regulators market is provided. The market is evaluated by collating revenues generated across segments, categorized by Type and Geography.
Report scope can be customized per your requirements. Click here.
Dyslipidemia, defined as elevated total or low-density lipoprotein (LDL) cholesterol levels, or low levels of high-density lipoprotein (HDL) cholesterol, is an important risk factor for coronary heart disease (CHD) and stroke. The prevalence of dyslipidemia increases in diabetic population.
According to a report by Yaru Li et al., published in PLoS One Journal 2018, the prevalence of dyslipidemia in the Chinese population was 39.9%, 46.8%, and 59.3% in population with normal glucose, prediabetes, and type 2 diabetes mellitus (T2DM). Moreover, the diabetic population has increased over the years.
As per a World Health Organization 2018 report, the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014, resulting in a rise in global prevalence of diabetes among adults over 18 years of age from 4.7% in 1980 to 8.5% in 2014. Hence, the increasing prevalence of diabetes may result in increasing prevalence of dyslipidemia.
The statins competitively inhibit HMG-CoA reductase. Statins are more effective than other lipid-regulating drugs at lowering LDL-cholesterol concentration. Hence, the demand for statins is expected to increase as prevalence of dyslipidemia increases.
In addition, the lipid regulatory market is being dominated by statin and most of the statin drugs patents are coming to an end and there would be an increased competition in the generics.
To understand key trends, Download Sample Report
According to OECD, the North American countries of United States and Mexico have one of the highest prevalence of Obesity and Diabetes in the world. Moreover, being overweight or obese increases the chances of developing the common type of diabetes, type 2 diabetes. As the presence of diabetes increases the risk of dyslipidemia, its prevalence is expected to increase.
However, the United States (US) and Canada have a developed and well-structured health care system. These systems also encourage research and development. These policies encourage global players to enter the US and Canada. As a result, these countries enjoy the presence of many global market players. As high and increasing demand is met by the presence of global players in the region, the market is further expected to increase.
To understand geography trends, Download Sample Report.
Majority of the lipid regulators are being manufactured by the global key players. Market leaders with more funds for research and better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing an emergence of some small players due to the rise of awareness. This has also helped the market grow.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Diabetes and Cardiac Diseases
4.2.2 Growing Geriatric Population
4.3 Market Restraints
4.3.1 Low Awareness of Lipid Regulators
4.3.2 Introduction of low cost generics
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Type
220.127.116.11 Branded statins
18.104.22.168 Statin combinations
22.214.171.124 Generic statins
126.96.36.199 Fibric-acid derivatives
188.8.131.52 Bile-acid sequestrants
184.108.40.206 Nicotinic acid derivatives
220.127.116.11 Other new products
5.2.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.2.4 Middle-East and Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle East and Africa
5.2.5 South America
22.214.171.124 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc
6.1.3 Andrx Corporation
6.1.5 Bristol-Myers Squibb
6.1.6 Merck KGaA
6.1.9 Teva Pharmaceuticals
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments